Back to Search
Start Over
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas
- Source :
- Science signaling. 10(507)
- Publication Year :
- 2017
-
Abstract
- Activation of the RAS-RAF-MEK-ERK signaling pathway is implicated in driving the initiation and progression of multiple cancers. Several inhibitors targeting the RAS-MAPK pathway are clinically approved as single- or polyagent therapies for patients with specific types of cancer. One example is the MEK inhibitor trametinib, which is included as a rational polytherapy strategy for treating EML4-ALK-positive, EGFR-activated, or KRAS-mutant lung cancers and neuroblastomas that also contain activating mutations in the RAS-MAPK pathway. In addition, in neuroblastoma, a heterogeneous disease, relapse cases display an increased rate of mutations in
- Subjects :
- Mice, Inbred BALB C
Lung Neoplasms
Oncogene Proteins, Fusion
MAP Kinase Signaling System
Pyridones
Receptor Protein-Tyrosine Kinases
Antineoplastic Agents
Mechanistic Target of Rapamycin Complex 2
Pyrimidinones
Xenograft Model Antitumor Assays
Mice
Neuroblastoma
Cell Line, Tumor
Animals
Humans
Anaplastic Lymphoma Kinase
Female
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-akt
Mitogen-Activated Protein Kinase 7
Subjects
Details
- ISSN :
- 19379145
- Volume :
- 10
- Issue :
- 507
- Database :
- OpenAIRE
- Journal :
- Science signaling
- Accession number :
- edsair.pmid..........d1cde475496be5bf21ac331c5354ae45